Dnd41

The studies were performed in human leukemia cell lines: REH (B cell acute lymphoblastic leukemia, B-ALL); DND-41 and MOLT-4 (T cell acute lymphoblastic leukemia, T-ALL); MOLM-14 and MV4-11 (acute myeloid leukemia, AML); and K562 (chronic myeloid leukemia, CML).
Human MOLT-4 and K562 cells were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK). The human cell lines: REH, DND-41, MOLM-14, and MV4-11 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany).
All cell lines were cultured in RPMI-1640 GlutaMax medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (100 Units/mL penicillin and 100 µg/mL streptomycin) (all reagents from Life Technologies, Carlsbad, CA, USA). The cells were maintained at 37 °C in a humidified 95% air and 5% CO₂.

Human T-cell leukemia cell lines (ALL-SIL, CCRF-CEM, DND-41, JURKAT, MOLT-4) were purchased from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany;). The cell lines were negative for mycoplasma contamination and were cultivated in RPMI-1640 medium with GlutaMAX™ supplemented with 10% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) under controlled conditions (37 °C, 5% CO₂). The cultured cells were split every two to three days and maintained in exponential growth phase. JURKAT stable clones that express the WT or mutant PTEN (G129R) under the control of the tetracycline-inducible system (Tet-on)^{34 (link)} were kindly provided by Dr. Arthur Weiss from the Howard Hughes Medical Institute (University of California, San Francisco, USA). PTEN G129R is a tumor-derived mutation that is defective in both the protein and the lipid phosphatase activity^{34 (link)}. Clones were maintained in RPMI-1640 medium with GlutaMAX™ supplemented with 10% Tet system-proved fetal calf serum and 2 mg/mL G418 and 300 µg/mL hygromycin B and expression of PTEN was induced by doxycycline (DOX), a tetracycline analog.

All cell lines were cultured in a humidified incubator at 37°C with 5% CO₂. The following cell lines were obtained from ATCC: HEK 293 T, WI-38, WI-38 VA 13, Daudi, EB1, HS604T, HS616T, HuT 102, MC116, Namalwa, H1963, H196, H209, H526, H524, H82, H69, Raji, SW1271, and TO175T. DEL, L428, SU-DHL-10, WSU-DLCL2, Jurkat, DND41 and SR768 were purchased from DSMZ. A4/Fuk was obtained from JCRB Cell Line Bank. OCI-Ly3 was a kind gift from Dr. Mark Minden (University Health Network Toronto). The human lung fibroblast cell lines WI-38 and WI-38 VA13 were routinely cultured in EMEM supplemented with 10% Fetal Bovine Serum (FBS). SCLC cell lines H1963, H196, SW1271, H209, H526, H524, H82 and H69 were maintained in RPMI 1640 with 10% FBS. The lymphoma cell lines EB1, Daudi, Raji, A4/Fukuda, Jurkat, DND41, WSU-DLCL2, DEL, HUT102, Namalwa and L428 were cultured in RPMI 1640 with 10% FBS. MC116 and SU-DHL-10 cells were maintained in RPMI 1640 with 20% FBS. OCI-Ly3 cells were cultured in IMDM with 20% FBS. The SR786 cell line was cultured in RPMI 1640 with 15% FBS. HS604T cells were maintained in DMEM with 10%FBS and 2 mM Glutamine. HS616T and TO175T cell lines were cultured in DMEM with 10% FBS. HEK 293 T cells were maintained in DMEM with 10% FBS. All cell lines were maintained with a cocktail of penicillin and streptomycin (Gibco).

B-ALL cell lines 380 (ACC 39), 697 (ACC 42) and T-ALL cell lines DND-41 (ACC 525), PEER (ACC 6) were purchased from DSMZ (Braunschweig, Germany). HeLa cells (American Type Culture Collection; cat. no. CCL-2) and ALL cell lines were cultured in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2 mM L-Glutamine (Gibco, Grand Island, NY) and maintained at 37 °C in 5% CO₂. All selected cell lines met our set criteria of having pediatric origins, similar to the patient samples we studies (See Supplementary Methods).

The human cell lines SUDHL-1, Karpas-299, HPB-ALL, DND41 and Jurkat were purchased from the DSMZ and were cultured in RPMI1640 supplemented with 10% FCS. The COST and PIO ALCL cell lines were developed in the Lamant laboratory and were grown in ISCOVE medium (Invitrogen, Cergy Pontoise, France) supplemented with 10% FCS. All the cell lines were subject to quarterly mycoplasma testing and are not on the ICLAC and NCBI Biosample misidentified cell list.